Dishman Carbogen Amcis Limited , a fully integrated Contract Development and Manufacturing Organisation (CDMO), is set to release its financial results for the second quarter of fiscal year 2026. The company has scheduled an earnings conference call to discuss its performance and financial outcomes for the quarter and half-year ended September 30, 2025.

Key Details of the Earnings Announcement

The earnings call will feature key management representatives, including Mr. Harshil Dalal, the Global CFO, and Mr. Stephan Fritschi, Chief Executive Officer of Carbogen Amcis Entities. They will lead the discussion on the company's financial results and overall performance for the period under review.

Company Profile

Dishman Carbogen Amcis Limited, established in 1983, has positioned itself as a global player in the pharmaceutical industry. The company offers end-to-end integrated CDMO services, specializing in:

• APIs (Active Pharmaceutical Ingredients)
• High Potent APIs
• Intermediates
• Phase Transfer Catalysts
• Vitamin D Analogues
• Cholesterol
• Lanolin-related products
• Antiseptic and Disinfectant formulations

With a strong global presence, Dishman Carbogen Amcis operates development and manufacturing sites across multiple countries, including Switzerland, UK, France, Netherlands, India, and China. This international footprint enables the company to cater to diverse market needs and maintain a competitive edge in the CDMO sector.

Investor Participation

For investors and analysts interested in joining the conference call, the company has provided multiple access options:

International Toll-Free Numbers:

• USA: 18773870849
• UK: 08000163439
• Singapore: 8001011941
• Hong Kong: 800903171

Primary Numbers:

• 086 3416 9132
• 086 4536 6496

To streamline the process and avoid long queues, participants can use the Express Join with DiamondPassTM pre-registration facility. This allows direct dial-in access without waiting for an operator.

The upcoming earnings call presents an opportunity for stakeholders to gain insights into Dishman Carbogen Amcis's financial health and strategic direction. As the company continues to navigate the dynamic pharmaceutical landscape, this quarterly update will be crucial for investors assessing the firm's performance and future prospects in the competitive CDMO market.

Dishman Carbogen Amcis Limited , a prominent player in the pharmaceutical industry, has announced a strategic move to simplify its corporate structure. The company has completed the merger of two of its material wholly-owned step-down subsidiaries in Switzerland, marking a significant step towards streamlining its operations.

Merger Details

The merger involves two entities:

Both companies are wholly-owned subsidiaries of CARBOGEN AMCIS Holding AG and material step-down subsidiaries of Dishman Carbogen Amcis Limited.

Business Operations

The merged entities share similar business activities:

• Trading of raw materials, intermediate and finished products for chemical and pharmaceutical industries
• Acquisition, investment, management, financing, and sale of assets
• Participation in domestic and foreign companies, particularly in the chemical and pharmaceutical sectors

Financial Implications

Both CASPAG and CAINAG reported nil turnover for the financial year ended March 31, 2025. The merger transaction does not involve any cash consideration or share exchange.

Rationale and Impact

The primary objective of this merger is to simplify the legal structure of the CARBOGEN AMCIS Group. This strategic move is expected to enhance operational efficiency and potentially reduce administrative overheads.

Dishman Carbogen Amcis Limited has confirmed that this merger will not affect its shareholding pattern. The company's equity structure remains unchanged.

Regulatory Compliance

The merger has received necessary regulatory approvals. As a related party transaction between two wholly-owned subsidiaries, it is exempted under Regulation 23(5)(c) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This corporate action reflects Dishman Carbogen Amcis Limited's approach to optimizing its global operations. By consolidating its Swiss subsidiaries, the company aims to position itself for potentially improved operational synergies in the pharmaceutical landscape.